FVFI
CARM

Flagship Ventures Fund IV’s Carisma Therapeutics CARM Stock Holding History

Flagship Ventures Fund IV’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$469K Buy
+73,321
New +$1.01M 0.12% 3

Other funds holding CARM

FVF2
Flagship Ventures Fund 2007 Cambridge, Massachusetts $95.2M AUM
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Flagship Ventures Fund IV's CARM Position: Q1 2016 in Review

Flagship Ventures Fund IV opened a new position in Carisma Therapeutics (CARM) in Q1 2016: 73,321 shares worth $469K. The stake represents 0.12% of the portfolio and ranks #3 among its holdings.

23 funds tracked by Wall St. Rank hold CARM as of Q1 2016.

  • Flagship Ventures Fund IV held 73,321 shares of Carisma Therapeutics worth $469K as of Q1 2016.
  • Carisma Therapeutics was a new Flagship Ventures Fund IV position in Q1 2016.
  • Carisma Therapeutics made up 0.12% of Flagship Ventures Fund IV's portfolio in Q1 2016, its #3 holding.
  • 23 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2016.

Based on Flagship Ventures Fund IV's 13F filing for Q1 2016, filed 13 May 2016.